Compare MXCT & STHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | STHO |
|---|---|---|
| Founded | 1999 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Real Estate |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.5M | 114.0M |
| IPO Year | 2021 | 2022 |
| Metric | MXCT | STHO |
|---|---|---|
| Price | $1.07 | $9.44 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.50 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 9.7K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.73 |
| EPS | ★ N/A | N/A |
| Revenue | $33,026,000.00 | ★ $110,143,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $7.05 |
| 52 Week High | $2.19 | $9.68 |
| Indicator | MXCT | STHO |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 60.83 |
| Support Level | $0.97 | $8.71 |
| Resistance Level | $1.16 | $9.68 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 7.00 | 69.74 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties, and land and development properties.